正在进行的对再辐射的前性研究:对临床试验数据库的系统审查
Jonas Willmann1, Panagiotis Balermpas1, Andreas Rimner2
1Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
概括
再辐射研究正在扩大,重点关注中枢神经系统,头和骨盆癌症. 需要更多的随机对照试验,特别是肺癌,乳腺癌和妇科癌,以优化治疗.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 临床试验 临床试验
背景情况:
- 由于改善癌症存活率和精确的辐射技术,再辐射正在引起人们的兴趣.
- 关于再辐射安全性和有效性的高质量前性证据有限.
- 本次审查评估了正在进行的前性研究,以确定研究缺口.
研究的目的:
- 系统地审查正在进行的前性再辐射研究.
- 确定再辐射临床实践中的研究缺口和优先事项.
- 为未来的临床试验设计和治疗策略提供信息.
主要方法:
- 使用与再辐射相关的搜索术语对ClinicalTrials.gov进行系统审查.
- 包括正在招聘或活跃的前性研究.
- 排除追溯,in-silico和已发表的研究,遵守PRISMA 2020指南.
主要成果:
- 包括99项前性研究,其中40%专注于中枢神经系统 (CNS) 的再辐射.
- 大多数研究都是干预性 (90%),其中有相当多的II期试验 (32%).
- 随机对照试验 (RCT) 是有限的 (16),与全身疗法的结合是常见的 (41%).
结论:
- 目前正在进行的再辐射研究主要针对中枢神经系统,头和骨盆癌症.
- 在肺癌,乳腺癌和妇科癌症中急需更多的RCT.
- 剂量升级,精确技术和全身疗法组合是优化再辐射时间表的关键.
相关概念视频
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328


